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Dystrophin restoration therapy improves
both the reduced excitability and the force
drop induced by lengthening contractions
in dystrophic mdx skeletal muscle
Pauline Roy1, Fredérique Rau1, Julien Ochala2, Julien Messéant1, Bodvael Fraysse1, Jeanne Lainé1, Onnik Agbulut3,
Gillian Butler-Browne1, Denis Furling1 and Arnaud Ferry1,4,5*
Abstract
Background: The greater susceptibility to contraction-induced skeletal muscle injury (fragility) is an important
dystrophic feature and tool for testing preclinic dystrophin-based therapies for Duchenne muscular dystrophy.
However, how these therapies reduce the muscle fragility is not clear.
Methods: To address this question, we first determined the event(s) of the excitation-contraction cycle which is/are
altered following lengthening (eccentric) contractions in the mdx muscle.
Results: We found that the immediate force drop following lengthening contractions, a widely used measure of muscle
fragility, was associated with reduced muscle excitability. Moreover, the force drop can be mimicked by an experimental
reduction in muscle excitation of uninjured muscle. Furthermore, the force drop was not related to major neuromuscular
transmission failure, excitation-contraction uncoupling, and myofibrillar impairment. Secondly, and importantly, the
re-expression of functional truncated dystrophin in the muscle of mdx mice using an exon skipping strategy partially
prevented the reductions in both force drop and muscle excitability following lengthening contractions.
Conclusion: We demonstrated for the first time that (i) the increased susceptibility to contraction-induced muscle injury
in mdx mice is mainly attributable to reduced muscle excitability; (ii) dystrophin-based therapy improves fragility of the
dystrophic skeletal muscle by preventing reduction in muscle excitability.
Background
Duchenne muscular dystrophy (DMD) is a severe disorder
affecting both skeletal and cardiac muscles resulting from
dystrophin deficiency. Dystrophin, a subsarcolemmal pro-
tein encoded by Dmd, is thought to play a role in sarco-
lemma stability, localization, and function of different
proteins that trigger damage process when absent [1, 2].
In the case of dystrophin deficiency, the skeletal muscle is
more fragile, i.e., more susceptible to damage caused by
high-force contractions both in situ and in vitro, such as
produced during lengthening contractions, also known as
eccentric contractions [3–6]. Lengthening contractions
occur when the muscle acts as a brake, to slow down
movement consequently. Cycles of muscle injury and in-
complete recovery occur and contribute to progressive
muscle weakness and loss in DMD patients.
The immediate force drop following lengthening con-
tractions is a widely used measure of the magnitude of
muscle damage caused by contraction in dystrophin-
deficient mdx mice [7], the most widely used mouse
model for DMD. Thus, it is an important tool for testing
preclinic dystrophin-based therapies for DMD. Interest-
ingly, dystrophin-based therapies reduce the extent of the
immediate force drop following lengthening contractions
in mdx mice [8–15]. However, it remains unclear how
these therapies reduce the susceptibility to lengthening
contraction-induced injury in mdx mice.
The immediate force drop following repetitive lengthen-
ing contractions observed in mdx muscles (>50 % after
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less than 10 contractions) is theoretically related to
changes in the cascade of events responsible for muscle
excitation and contraction. It results from a failure in
neuromuscular transmission, reduced muscle excitability,
impaired calcium release and uptake in the sarcoplasmic
reticulum, and/or contractile impairment. However, the
precise events of the cycle of excitation-contraction re-
sponsible for the immediate force drop following length-
ening contractions are still being clarified. A recent work
postulates that neuromuscular transmission failure con-
tributes to the greater force drop following lengthening
contractions in mdx mice [16, 17]. Another recent study
suggests that reduced muscle excitability is a major mech-
anism of the greater force drop in mdx mice [18]. More-
over, it was previously proposed that the greater force
drop in mdx mice results from myofibrillar impairment
due to structural damage [19, 20]. Overall, these finding
revealed that the mechanisms of the greater force drop
following lengthening contractions in mdx are variable
and somewhat contradictory.
The aims of the present study were to (i) determine
the altered event(s) of the excitation contraction cycle
leading to the immediate force drop following lengthen-
ing contractions in mdx mice and (ii) demonstrate that
dystrophin restoration-based therapy improves the de-
fective event(s) of the excitation-contraction cycle. In
the present study, we studied neuromuscular transmis-
sion, muscle excitability, excitation-contraction coupling,
and myofibrillar function in the hindlimb skeletal muscle
of mdx mice, by combining a broad range of biophysical
and biological assays. The restoration of dystrophin ex-
pression in mdx mice was performed by Dmd exon 23
skipping strategy [10].
Methods
Animals
All procedures were performed in accordance with the
National and European legislations. Mdx mice (mdx,
C57BL/10ScSc-DMDmdx/J) and sex- and age-matched
wild-type control mice (C57) (healthy) were used at 3–
6 months of age.
Whole muscle force production in response to electrical
stimulation
Maximal tetanic isometric force and susceptibility to
contraction-induced injury (see below) were evaluated
by measuring the in situ tibialis anterior (TA) and extensor
digitorum longus (EDL) muscle contraction in response to
nerve stimulation, as described previously [21, 22]. Mice
were anesthetized using pentobarbital (60 mg/kg ip). Body
temperature was maintained at 37 °C using radiant heat.
The knee and foot were fixed with pins and clamps, and
the distal tendon of the muscle was attached to a lever
arm of a servomotor system (305B, Dual-Mode Lever,
Aurora Scientific, Aurora, Canada) using a silk ligature.
The sciatic nerve was proximally crushed and distally
stimulated by a bipolar silver electrode using supramaxi-
mal square wave pulses of 0.1-ms duration (10 V). We
measured the absolute maximal force that was generated
during isometric tetanic contractions in response to elec-
trical stimulation (125 Hz, 500 ms). Absolute maximal
force was determined at L0 (length at which maximal ten-
sion was obtained during the tetanus). Absolute maximal
force was normalized to the muscle weight as an estimate
of specific maximal force (absolute maximal force/muscle
weight). In some case, submaximal force in response to
nerve stimulation (25 Hz, 500 ms) was also measured to
calculate the 25 Hz/125 Hz force ratio.
Susceptibility to contraction-induced injury was esti-
mated from the force drop resulting from lengthening
contraction-induced injury. The sciatic nerve was stimu-
lated for 700 ms (frequency of 125 Hz). A maximal iso-
metric contraction of the TA muscle was initiated during
the first 500 ms. Then, muscle lengthening (10 % L0) at a
velocity of 5.5 mm/s (0.85 fiber length/s) was imposed
during the last 200 ms. Nine lengthening contractions of
the muscle were performed, each separated by a 60-s rest
period. All contractions were made at an initial length L0.
Maximal isometric force was measured 60 s after each
lengthening contraction and expressed as a percentage of
the initial maximal force.
In some cases, before and after the last lengthening
contraction, stimulating electrodes were applied directly
on the muscle, which was injected, or not with tubocurar-
ine, a neuromuscular transmission blocker. Direct muscle
stimulation was performed in order to evaluate neuromus-
cular transmission (without tubocurarine injection) and
muscle excitability (with tubocurarine injection). Compari-
sons between nerve (10 V) and muscle (80 V) stimulations
were made to evaluate nerve-muscle communication [23].
A lower force produced in response to nerve stimulation
versus muscle stimulation was indicative of a defect in
neuromuscular transmission. We increased the muscle
stimulation strength (5–95 V) to determine the voltage
strength needs to produce 50 % of maximal force, an
index of muscle excitability.
Data was acquired with a sampling rate of 100 kHz
(Powerlab 4/25, ADInstrument, Oxford, UK). After
contractile measurements, the animals were killed by
cervical dislocation and muscles were weighed.
Muscle action potential
Electromyography was performed with anesthetized mice
(pentobarbital, 60 mg/kg ip) in order to complete the evalu-
ation of neuromuscular transmission and muscle excitabil-
ity (see above). For compound muscle action potential
(CMAP) recordings, two monopolar needle electrodes were
inserted into the belly of the TA muscle. The recording
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(cathode) and the reference (anode) electrodes were
inserted, respectively, into the 1/3 proximal and the distal
portion of the muscle. A third monopolar electrode was
inserted in the contralateral hindlimb muscle to ground
the system. Data was amplified (BioAmp, ADInstrument),
acquired with a sampling rate of 100 kHz, and filtered at
5 kHz low pass and 1 Hz high pass (Powerlab 4/25, ADIn-
strument). Recording electrodes were positioned to
achieve maximal CMAP amplitude.
Nerve stimulations (0.1 ms, 10 V, 3 Hz and 10 Hz,
stimulation trains for 20 s) were applied to the sciatic
nerve, and CMAP was recorded to search for decre-
menting response to repetitive stimulation, used as a
marker of neuromuscular transmission failure [24].
CMAP amplitude was measured peak-to-peak and was
expressed as percentage of the first CMAP. CMAP were
also recorded during lengthening and isometric contrac-
tions, and we calculated the root mean square (RMS) of
CMAP, as an index of CMAP amplitude. RMS of each
CMAP corresponding to each contraction was then
expressed as a percentage of the first contraction, used
as a marker of muscle excitability.
Myofibrillar contractility
To evaluate myofibrillar contractility, skinned fibers
were studied as previously described [25]. Immediately
after the lengthening contractions, TA muscles were dis-
sected and placed in an ice-cold relaxing solution (in
mmol/l: 100 KCl, 20 Imidazole, 7 MgCl2, 2 EGTA, 4
ATP, pH 7.0; 4 °C). Small bundles of ~25–50 fibers were
dissected free from the muscle and tied to a glass micro-
capillary tube at ~110 % resting length. The bundles
were then placed in a skinning solution (relax solution
containing glycerol; 50:50 v/v) at 4 °C for 24 h and
subsequently treated with a cryoprotectant (sucrose
solution) for long-term storage at −80 °C as described
earlier [26]. On the day of the experiment, a bundle
was desucrosed and single fibers isolated. A fiber segment
length of 1 to 2 mm was then left exposed to the relaxing
solution between connectors leading to a force transducer
(model 400A, Aurora Scientific) and a lever arm system
(model 308B, Aurora Scientific). The apparatus was
mounted on the stage of an inverted microscope (model
IX70; Olympus). While the fiber segment was in relaxing
solution, the sarcomere length was set to 2.50 ± 0.05 μm
by adjusting the overall segment length. The sarcomere
length was controlled during the experiments using a
high-speed video analysis system (model 901A HVSL,
Aurora Scientific). The fiber segment width, depth, and
length between the connectors were measured. Fiber
cross-sectional area (CSA) was calculated from the diam-
eter and depth, assuming an elliptical circumference, and
was corrected for the 20 % swelling that is known to occur
during skinning. At 15 °C, immediately preceding each
activation, the fiber segment was immersed for 10–20 s in
a solution with a reduced Ca2+-EGTA buffering capacity.
This solution is identical to the relaxing solution except
that the EGTA concentration is reduced to 0.5 mM, which
results in more rapid attainment of steady force during
subsequent activation. Maximal isometric force was calcu-
lated as the difference between the total force in activating
solution (pCa 4.5) and the resting force measured in the
same segment while in the relaxing solution. Maximal
force was adjusted for fiber CSA and termed specific max-
imal force (P0). After mechanical measurements, each
fiber was placed in urea buffer in a plastic microcentrifuge
tube and stored at −80 °C until analysis by gel electrophor-
esis. The myosin heavy chain (MHC) isoform composition
of fibers was determined by 6 % SDS-PAGE. The acryl-
amide concentration was 4 % (w/v) in the stacking gel
and 6 % in the running gel, and the gel matrix included
30 % glycerol. Sample loads were kept small (equivalent
to ~0.05 mm of fiber segment) to improve the reso-
lution of the MHC bands (slow and fast MyHC: types I,
IIa, IIx, and IIb). Electrophoresis was performed at
120 V for 24 h with a Tris-glycine electrode buffer (pH
8.3) at 15 °C (SE 600 vertical slab gel unit, Hoefer Sci-
entific Instruments). The gels were silver-stained and
subsequently scanned in a soft laser densitometer (molecu-
lar dynamics) with a high spatial resolution (50 μm pixel
spacing) and 4096 optical density levels. Fibers were either
expressing the type IIx or IIb MHC isoforms. As the force
measurements were not different between these two types,
data were pooled together.
Muscle fiber ultrastructure
To evaluate fiber ultrastructure integrity immediately
after lengthening contractions, electron microscopy was
performed on TA muscles first fixed with 2 % PFA, 2 %
glutaraldehyde in 0.1 M phosphate buffer (pH 7.4), and
then with 2 % OsO4 in 0.1 M phosphate buffer for 1 h
at 4 °C. Muscles were then dehydrated at 4 °C in graded
acetone including a 1 % uranyl acetate in 70° acetone
staining step, before Epon resin embedding. Thin (70 nm)
sections were stained with uranyl acetate and lead citrate
and observed using a Philips CM120 electron microscope
(Philips Electronics NV) and photographed with a digital
SIS Morada camera.
Acetylcholine receptor morphology
Acetylcholine receptors (AChR) staining on isolated
muscle fibers was performed as described previously
[27]. Briefly, TA muscles were dissected immediately
after lengthening contractions and fixed in 4 % PFA/PBS
for 30 min and rinsed with PBS, pH 7.5, at room
temperature. Isolated muscle fibers were incubated for
15 min with 100 mM glycine in PBS and rinsed in PBS.
Samples were permeabilized and blocked in blocking
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buffer (3 % BSA/5 % goat serum/0.5 % Triton X-100/
PBS) for 4 h at room temperature. They were then incu-
bated overnight at 4 °C with α-bungarotoxin (α-BTX)
Alexa Fluor® 488 conjugate (Life Technologies, 1/1000)
in blocking buffer. Finally, after four 1-h washes in PBS,
muscles were flat-mounted in Vectashield (Vector Labs)
mounting medium. Confocal images were acquired using
Leica SPE confocal microscope with a Plan Apo ×63 NA
1.4 oil objective (HCX; Leica). Confocal software (LAS
AF; Leica) was used for acquisition of Z serial images,
with a Plan Apo ×63 NA 1.4 oil objective (HCX; Leica).
Confocal images presented are single-projected image
derived from image stacks. For all imaging, exposure set-
tings were identical between compared samples and ge-
notypes. Quantifications were done as previously [28],
using ImageJ software (version 1.46 m). Total neuromus-
cular junction area was determined by delineating the
outside edges of AChR clusters. AChR rich-endplate
area per neuromuscular junction corresponds to the oc-
cupied area of α-bungarotoxin fluorescent signal.
Exon skipping-based dystrophin restoration
The restoration of dystrophin expression was performed
by Dmd exon 23 skipping strategy using optimized U7-
small nuclear RNA (snRNA) antisense sequence (U7ex23)
previously described [10, 25]. Adeno-associated vectors
(AAV1) carrying the U7ex23 constructs were injected in
Tibialis anterior TA muscles from mdx mice. Titer for
AAV1-U7ex23 was 1.2 × 1012 vector genomes (vg)ml−1.
Briefly, mice were anesthetized (2–4 % isoflurane) and TA
muscles of the right hindlimb were injected (40 μl, 5.0 ×
1010 vg). Control muscle was obtained from the left hind
limb injected with saline solution only. Muscles were col-
lected 3 weeks after injection.
RNA isolation and quantification of Dmd Exon 23
skipping
In order to assess the level of exon 23 skipping, RT-PCR
analysis was done. Total RNA was isolated from TA
muscle samples using Tri Reagent (Sigma) according to
the manufacturer’s protocol. One microgram of RNA
was reverse transcribed using Enhances Avian Reverse
Transcriptase (eAMV™ RT), according to the manufac-
turer’s instruction (Sigma). Non-skipped and skipped
dystrophin transcripts were detected by nested PCR and
quantified as previously described [29]. The ratio of exon
inclusion/exclusion was quantified with ImageJ software
and as a percentage of inclusion/exclusion relative to
total intensity of isoform signals.
Quantitative PCR for dystrophin
The level of dystrophin messenger RNA (mRNA) was
assessed by q-PCR analysis using a Lightcycler 480
(Roche). Reactions were performed with SYBR Green kit
(Roche) according to the manufacturer’s instructions.
PCR cycles were a 15-min denaturation step followed by
50 cycles with 94 °C denaturation for 15 s, 58 °C anneal-
ing for 20 s, and 72 °C extension for 20 s. Mouse Rrlp0
mRNA was used as standard. Data were analyzed with
the Lightcycler 480 analysis software. Primer sequences:
mouse Dmd forward: 5′-TGGATCTGACATCTCATCAAG
GAC-3′; mouse Dmd reverse: 5′-CCATGCTAGCTACCCT
GAGAC-3′; mouse Rrlp0 forward: 5′-GAGGACCTCACT
GAGATTCGG-3′; mouse Rrlp0 reverse: 5′-TTCTGAGCT
GGCACAGTGAC-3′.
Western blot analysis of dystrophin
To confirm the presence of dystrophin protein expres-
sion, Western blots were performed. Total protein was
extracted from TA muscle samples with lysis buffer
(50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 % Triton,
1 % sodium deoxycholate, 0.1 % SDS, and Complete Pro-
tease inhibitor cocktail (Roche)) and quantified using
BCA Protein Assay Kit (Thermo Scientific Pierce). After
a denaturation step for 5 min at 95 °C, 50 μg of total
protein extract was loaded in Novex 4–12 % Bis-Tris
protein gels (Life Technologies) and transferred to nitro-
cellulose membrane. Blots were blocked for 1 h with
10 % non-fat milk in Tris-buffered saline. Dystrophin
and alpha-actinin proteins were detected by probing the
membrane with 1:100 dilution of monoclonal NCL-
DYS-1 primary antibody (Novocastra) and 1:1000 of
monoclonal anti-alpha-actinin primary antibody (Sigma),
respectively. An incubation with 1:5000 of sheep anti-
mouse secondary antibody (horseradish peroxidase conju-
gated) allowed visualisation using Substrat HRP Immobilon
Western (Millipore). Band intensities were analyzed using
ImageJ software.
Statistical analysis
Groups were statistically compared using one- or two-
way analysis of variance (lengthening contractions, geno-
type × lengthening contractions…) and Student’s t test. If
necessary, subsequent Bonferroni post hoc test was also
performed. Values are means ± SEM.
Results
Force dramatically drops after lengthening contractions
in mdx but not C57 mice
By analyzing in situ TA isometric muscle force produc-
tion in response to tetanic nerve stimulation (125 Hz,
500 ms), we observed an immediate force drop following
the third, sixth, and ninth lengthening contractions in
mdx mice (p < 0.05) (Fig. 1a, b). There was no major
force drop in C57 mice (Fig. 1b). In contrast, there was
no force drop following isometric contractions in mdx
mice (p > 0.05), indicating that the force drop was re-
lated to the muscle lengthening, but not fatigue, and
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may be due to the higher force production which oc-
curs during lengthening versus isometric contractions
(+65.9 ± 3.6 % in mdx mice and +68.9 ± 4.0 % in C57
mice). It should be noted that maximal force was not
fully recovered even after 30 min of recovery (Fig. 1c).
Is neuromuscular transmission impaired?
To determine whether neuromuscular transmission fail-
ure contributes to force drop, we performed electrical
TA muscle stimulation that can directly initiate muscle
action potentials, without the need of neuromuscular
transmission [30, 31]. Stimulating electrodes were posi-
tioned on the midbelly of the muscle, and the muscle
was stimulated with a high strength voltage (80 V). Under
basal conditions (before lengthening contractions), nerve
and muscle stimulations produced the same maximal
force (data not shown). We found that direct muscle
stimulation with a high strength voltage did not markedly
improve maximal force production after the nine length-
ening contractions in mdx mice (Fig. 1b).
Moreover, we performed electromyographic measure-
ments in order to measure CMAP decrement following
repetitive nerve stimulation (0.1 ms, 3 and 10 Hz, 20 s).
CMAP (amplitude) decrement following 3 or 10 Hz
stimulation was higher in the case of neuromuscular
transmission failure [24]. We found no 3 and 10 Hz
CMAP decrement differences between mdx and C57
mice before and after the nine lengthening contractions
(Fig. 2a, b).
To determine whether lengthening contractions cause
immediate neuromuscular junction structural changes in
mdx mice as previously described [17], fibers from the
TA muscle were stained with α-BTX to label acetylcho-
line receptor (AChR) clusters. Subsequently, z-serial im-
ages were collected with a confocal microscope and
collapsed into single images. Neuromuscular junctions
of mdx mice were severely fragmented before lengthen-
ing contractions (Fig. 2c). Indeed, postsynatic network
Fig. 1 Susceptibility to contraction-induced muscle injury, i.e., force drop
following lengthening contractions in TA muscle from mdx mice and
neuromuscular transmission. a Example of force traces during
lengthening contractions in mdx mice. The 10th contraction was
isometric. b Force drop following lengthening and isometric contractions
in mdx and C57 mice. c Force drop following nine lengthening
contractions in mdx mice, recovery, and direct muscle stimulation
with high voltage. Mdx LC lengthening contractions in mdx mice,
Mdx IC isometric contractions in mdx mice, C57 LC lengthening
contractions in C57 mice, 0LC before lengthening contractions, 9LC
after nine lengthening contractions, 9LC + muscle stimul stimulating
electrodes were located on the muscle after the ninth contractions,
9LC + recovery 30 min force was measured 30 min after the ninth
lengthening contractions, a significantly different from before
lengthening contractions (p < 0.05), b significant difference between
strains (p < 0.05), c significant difference from 9LC (p < 0.05). n = 8–21
per group
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was discontinuous and isolated AChR clusters were
observed, indicating a severe dismantlement of neuro-
muscular junctions. In contrast, AChR clusters exhibited
characteristic pretzel-like morphology, with complex con-
tinuous branched network, in C57 mice (Fig. 2d). Import-
antly, the nine lengthening contractions did not appear to
markedly affect neuromuscular junction morphology, in
both mdx and C57 (Fig. 2e, f). We measured the total
neuromuscular junction area, defined by the area con-
tained within a boundary encompassing the outermost
edges of the neuromuscular junction, as revealed by α-
BTX label. We found a decrease in total neuromuscular
junction area in mdx mice following the nine lengthening
contractions (p < 0.05) but not in C57 mice (Table 1).
Since the neuromuscular junction area contained within
the outside boundary does not really reflected the occu-
pied area of AChR clusters, we also measured the
AChR-rich endplate area per neuromuscular junction
corresponding to the α-BTX-labeled area per synapse.
Accordingly, the occupied AChR cluster area was also
reduced following the nine lengthening contractions in
mdx mice (p < 0.05) (Table 1). However, the complexity
Fig. 2 Neuromuscular transmission and neuromuscular junction morphology following lengthening contractions in the TA muscle from mdx
mice. a Compound muscle action potential (CMAP) (amplitude) in response to 3 Hz nerve stimulation. b CMAP (amplitude) in response to 10 Hz
nerve stimulation. c–f representative images of neuromuscular junction morphology using α-bungarotoxin staining. Bar = 20 μm. CMAP
compound muscle action potential, Mdx + 9LC after nine lengthening contractions, Mdx LC lengthening contractions in mdx mice, Mdx and
C57 before lengthening contractions. n = 6–13 per group for a and b
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within neuromuscular junction (calculated as (AChR-rich
endplate area/total neuromuscular junction area)*100)
was unchanged following the nine lengthening contrac-
tions in mdx mice (Table 1). Moreover, we found no effect
of the nine lengthening contractions on the number of
fragments and the area of each AChR fragment in mdx
mice (Table 1).
Together, these results indicate that neuromuscular
transmission failure was not a major mechanism of
the force drop following lengthening contractions in
mdx mice.
Is muscle excitability depressed?
A decreased generation and propagation of muscle ac-
tion potential, i.e., reduced muscle excitability, could
contribute to the force drop following lengthening con-
tractions. To test this hypothesis, we simultaneously
measured maximal force and CMAP (RMS) during
lengthening contractions. We found that CMAP in re-
sponse to nerve stimulation (0.1 ms, 500 ms, 125 Hz)
decreased following lengthening contractions in mdx
mice (p < 0.05), similar to maximal force, but not in C57
mice (Fig. 3a). In contrast, CMAP did not decrease in
mdx mice following isometric contractions (Fig. 3b).
Next, we determined the necessary muscle stimulation
strength (in V) for 50 % of maximal force production
when the muscle is directly activated, i.e., not excited via
neuromuscular transmission. TA muscles were injected
with tubocurarine (15 μl at 0.07 mg/ml), a neuromuscular
transmission blocker. The stimulating electrodes were po-
sitioned on the muscle surface. We found that the voltage
needed to elicit 50 % of maximal force markedly increased
following the nine lengthening contractions (Fig. 3c)
(p < 0.05), indicating an increased threshold for action
potential generation, confirming reduced excitability.
Then, we determined the relationship between CMAP
(RMS) and force in intact mdx muscles (that did not
performed lengthening contractions) to determine whether
an experimental reduction in CMAP caused a proportional
decreases in force. TA muscles from mdx mice were
injected with various doses of tubocurarine (15 μl at 0.007–
0.07 mg/ml) in order to pharmacologically reduced CMAP,
and force was measured 5 to 15 min after. We found that
absolute maximal force decreased proportionally with
CMAP (Fig. 3d). In fact, linear regression analysis revealed
a strong correlation between CMAP and absolute maximal
force (r2 = 0.93) (p < 0.0001). Since the slope of the regres-
sion line was ~1 (0.94 ± 0.03), a given reduction in CMAP
caused a similar decrease in force. Therefore, the force drop
following lengthening contractions could be mimicked by
an experimental reduction in CMAP, i.e., muscle excitation.
Together, these results indicate that the reduced muscle ex-
citability contributes to the force drop following lengthen-
ing contractions in mdx mice.
To determine whether reduced muscle excitability was
also reduced in C57 mice when the force drop is import-
ant, they performed 12 × 20 % L0 lengthening contrac-
tions, a more severe lengthening contraction protocol
than the protocol used for mdx mice (9 × 10 % L0
lengthening contractions). We found that 12 × 20 % L0
lengthening contractions induced a marked force drop
(up to −67 %) in C57 mice (Fig. 3e, f ). Electromyography
analysis indicated that CMAP was also decreased follow-
ing 12 × 20 % L0 lengthening contractions in C57 mice
(p < 0.05), but not isometric contractions (Fig. 3e). More-
over, muscle stimulation with high strength current
(80 V) did not markedly reduce the force drop following
lengthening contractions in C57 mice (Fig. 3f), indicating
that the reduced CMAP was independent from neuro-
muscular transmission failure. Together, these results sug-
gest that reduced muscle excitability is also a mechanism
of the force drop following lengthening contractions in
C57 mice.
With the aim to increase muscle excitability, mdx mice
were treated, before the lengthening contractions, with
salbutamol that activates the Na+,K+ pump [32]. A re-
cent study suggests that the Na+,K+ pump is depressed
in mdx mice at the basal state, i.e., before lengthening
contractions [33]. We found that salbutamol administra-
tion (2 mg/kg, ip) did not reduce the force drop following
lengthening contractions (Fig. 4a), even though the initial
maximal force (before lengthening contractions) was re-
duced by salbutamol (Fig. 4b) (p < 0.05). Mdx mice were
then treated after the ninth lengthening contraction, with
Table 1 Morphology parameters of neuromuscular junction following lengthening contractions in mdx mice
Mdx Mdx + 9LC C57 C57 + 9LC
Total NMJ area (μm2) 2067.6 ± 145.7 1678.9 ± 83.0a 1025.2 ± 69.0 1065.8 ± 44.3
AChR area/NMJ (μm2) 1005.2 ± 68.7 775.3 ± 30.3a 512.6 ± 29.3 590.1 ± 33.0
Complexity within NMJ (%) 47.6 ± 2.2 48.7 ± 1.3 50.7 ± 1.7 56.0 ± 2.3
AChR fragment number 31.3 ± 2.7 29.1 ± 1.7 3.1 ± 0.7 3.5 ± 0.4
AChR fragment area (μm2) 75.6 ± 29.1 34.7 ± 4.3 276.6 ± 60.7 260.5 ± 34.7
n > 30 (C57) or >60 (mdx) per group (from 3 C57 mice and 4 mdx mice)
NMJ neuromuscular junction, AChR acetylcholine receptor, Mdx or C57 before nine lengthening contractions, Mdx + 9LC after nine lengthening contractions,
C57 + 9LC after nine lengthening contractions
aSignificantly different from before nine lengthening contractions (p < 0.05)
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Fig. 3 Muscle excitability following lengthening contractions in the TA muscle from mdx mice. Compound muscle action potential (CMAP) was
measured in response to nerve (a, b, and d) or muscle stimulation (c). a CMAP (root mean square, RMS) in response to nerve stimulation recorded
during lengthening contractions in mdx mice. The force drop was also shown. b CMAP (RMS) in response to nerve stimulation recorded during
lengthening or isometric contractions in mdx mice. The force drop was also shown. c Voltage strength (V) needs to obtain 50 % of maximal force in
response to muscle stimulation when neuromuscular transmission was inhibited by tubocurarine in mdx mice. d Force and CMAP (RMS) relationship
obtained when CMAP in response to nerve stimulation was experimentally reduced by tubocurarine, in the mdx muscle at the basal state (before
lengthening contractions). e CMAP (root mean square, RMS) in response to nerve stimulation recorded during lengthening and isometric contractions
in C57 mice. The force drop was also shown and was induced by a severe lengthening contraction protocol (12 × 20 % L0). f Force drop following
nine lengthening contractions in C57 mice and direct muscle stimulation with high voltage (80 V). CMAP compound muscle action potential,
Mdx + 9LC after nine lengthening contractions in mdx mice, Mdx LC lengthening contractions in mdx mice, Mdx IC isometric contractions in
mdx mice, 12LC (20 % L0) 12 × 20 % lengthening contractions were performed in C57 mice, 12LC(20 % L0) +muscle stimul stimulating electrodes were
located on the muscle after 12 × 20 % L0 lengthening contractions in C57 mice, C57 LC 12 × 20 % L0 lengthening contractions in C57 mice, C57 IC 12
isometric contractions in C57 mice, a significantly different from before lengthening contractions (p < 0.05), b significant difference between strains
(p < 0.05), c significant difference from IC (p < 0.05). n = 6–13 per group
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anthracene-9-carboxylic acid (9AC) (30 mg/kg, ip) that in-
creases muscle excitability via an inhibition of the chloride
channel [34]. Mdx mice were treated after (and not before)
the lengthening contractions, to avoid complications
due to 9AC-induced slowing of the relaxation during
lengthening contractions. We found that 9AC treat-
ment improved the maximal force 10 min after the last
lengthening contraction in mdx mice (Fig. 4c) (p < 0.05).
Finally, mdx mice were treated before the lengthening
contractions with mexiletine (40 mg/kg, ip), a sodium
channel blocker, that reduced muscle excitability [34]. We
confirmed that mexiletine decreased CMAP in mdx mice
before lengthening contractions (Fig. 4d) (p < 0.05). Since
mexiletine also induces a tetanic fade (decrease in force
within a train of stimulation) with the usual 125-Hz
stimulation, we performed 75 Hz stimulation that did
Fig. 4 Effect of pharmacological modulation of muscle excitability (salbutamol, 9AC, mexiletine) in the TA muscle from mdx mice. a Force drop
following lengthening contractions in mdx mice treated with salbutamol. b Maximal force before lengthening contractions (initial) in mdx mice
treated with salbutamol. c Force drop following nine lengthening contractions in mdx mice treated with anthracene-9-carboxylic acid (9AC).
d CMAP (RMS) during 125 Hz stimulation in mdx mice treated with mexiletine, before lengthening contractions. e Force and CMAP (RMS) drops
following lengthening contractions in mdx mice treated with mexiletine. f Maximal force before lengthening contractions in mdx mice treated
with mexiletine. CMAP compound muscle action potential, Mdx + Salbu mdx mice treated with salbutamol, Mdx + 9AC mdx mice treated with
9AC, Mdx +Mexi mdx mice treated with mexiletine, Mdx LC lengthening contractions in mdx mice, a significantly different from before lengthening
contractions (p < 0.05), c significant difference with non-treated mice (p < 0.05). n = 6–15 per group
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not produce such a phenomenon. We found that
mexiletine treatment had no effect on either force or
CMAP—during lengthening contractions (Fig. 4d, e),
suggesting that alteration in sodium channels does not
contribute to the reduced excitability following lengthen-
ing contractions. It should be noted that mexiletine did
not alter initial maximal force (before lengthening con-
tractions) (Fig. 4f). Together, these results may suggest
that the reduced excitability following lengthening con-
tractions results, at least partly, from an alteration in
chloride channels but not in either the Na+,K+ pump or
sodium channels.
Is the excitation-contraction uncoupled?
We then tested the possibility that a defect in excitation-
contraction coupling also contributes to the force drop
in mdx mice. A decrease in the ratio of the force at low
frequency (25 Hz) to the force at high-frequency (125 Hz)
stimulation following lengthening contractions was used
as a marker of excitation-contraction uncoupling [35, 36].
At low frequency, insufficient calcium would be re-
leased (resulting in reduced submaximal force) that
could be overcome by high-frequency stimulation
(resulting in near normal maximal force). Figure 5a
showed that the 25 Hz/125 Hz force ratio did not
decrease following lengthening contractions in mdx
mice. These results suggest that excitation-contraction un-
coupling did not contribute to the force drop following
lengthening contractions in mdx mice. However, it
remains to be confirmed if this ratio can be applicable to
test excitation-contraction coupling following lengthening
contractions in mdx muscle.
Is the calcium release also limited because of RyR
alteration?
To determine whether the force drop following length-
ening contractions was also increased by further ryano-
dide receptor (RyR) dysfunction [37, 38], we treated mdx
mice with caffeine or dantrolene, two pharmacological
agents known to increase or reduce calcium release by
modulating RyR functions [35, 39]. Our hypotheses were
that caffeine or dantrolene would increase or decrease
the calcium leak related to RyR dysfunction, thus the
force drop following lengthening contractions. The re-
sults shown that caffeine (8 mg/kg, ip) increased the
force drop following lengthening contractions in mdx
mice (Fig. 5b). However, dantrolene (15 mg/kg, ip) did
not reduce it (Fig. 5b). It should be noted that dantrolene
reduced maximal force before lengthening contraction
(Fig. 5c). These results suggest that a further worsening of
RyR dysfunction following lengthening contractions did
not contribute to the force drop in mdx mice since dan-
trolene did not improve it.
Is the contractile apparatus preserved?
We then tested the possibility that lengthening cont-
ractions altered myofibrillar function. Immediately
following in situ the nine lengthening contractions,
Fig. 5 Excitation-contraction coupling (25 Hz/125 Hz force ratio)
following lengthening contractions and effect of pharmacological
modulation of ryanodine receptor (caffeine, dantrolene) in the TA
muscle from mdx mice. a Ratio of 25 and 125 Hz forces following
lengthening contractions in mdx mice, used as an index of
excitation-contraction coupling. b Force drop following lengthening
contractions in the TA muscle from mdx mice treated with caffeine or
dantrolene, i.e., modulators of ryanodine receptor. c Maximal force
before lengthening contractions (initial) in the TA muscle of mdx mice
treated with caffeine or dantrolene. Mdx + Caf mdx mice treated with
caffeine, Mdx + Dant mdx mice treated with dantrolene, a significantly
different from before lengthening contractions (p < 0.05), c significant
difference with non-treated mice (p < 0.05). n = 6–10 per group
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skinned fibers were prepared from the TA muscle and
maximal activated calcium force was measured in both
mdx and C57 mice. We found no reduction in maximal
activated calcium force following the nine lengthening
contractions in both mdx- and C57-skinned fibers ex-
pressing the types IIx and IIb MHC isoforms (Fig. 6a)
(p > 0.05), indicating that myofibrillar dysfunction did
not contribute to the force drop following lengthening
contractions in mdx mice.
Accordingly, we observed that lengthening contractions
induced no major change in sarcomere ultrastructure,
using electron microscopy (Fig. 6b, c). In line with previ-
ous studies [40], we did find morphological abnormalities
in some TA muscle fibers of mdx mice before lengthening
contractions, such as enlarged SR cisternae, focal Z-line
absence or streaming, degenerating fibers, and central nu-
clei (data not shown). However, a thorough comparison of
the contralateral muscle fixed immediately after the nine
lengthening contractions did not reveal any specific add-
itional lesions, such as sarcolemmal ruptures, sarcomere
tearing, thus arguing against any structural injuries
directly linked to lengthening contractions in mdx
mice (Fig. 6c).
In agreement with these previous findings, we found
no indication of reduced myofilament overlapping, i.e.,
disrupted sarcomeres, which has been proposed to be
responsible for the force drop following lengthening
contractions in healthy mice. The popping-sarcomere
hypothesis is based on the proposal that during muscle
lengthening, the length change will be taken up by the
weakest sarcomeres, resulting in no myofilament overlap
in the latter ones [41]. At the end of the lengthening,
these overstretched sarcomeres do not re-interdigitate,
and thus a shift in muscle optimal length for maximal
force production (L0) would occur. To test this mechan-
ism, we determined whether muscle recovered maximal
force following the nine lengthening contractions when
an attempt was made to reach a possible new L0. As
showed in Fig. 6d, maximal force was only slightly im-
proved after this procedure, indicating that the presence
of overstretched sarcomeres/sarcomere disruption is not
the major explanation for the force drop in mdx mice.
Are freshly regenerated fibers more fragile?
To test the possibility that it is the presence of freshly
regenerated fibers but not the dystrophin deficiency
per se that causes the susceptibility to lengthening
contraction-induced muscle damage, cardiotoxin (10 μM,
50 μl), a myotoxic agent, was injected into TA muscles
from mdx mice as described [42]. We found that the force
drop following lengthening contractions was not increased
by cardiotoxin injection in mdx and C57 mice (Fig. 6e)
(p > 0.05), at a time (21-day postinjection) where the
regenerating muscle have recovered its maximal force
production (Fig. 6f). This result indicated that recent
muscle degeneration/regeneration was not the cause of
the susceptibility to lengthening contraction-induced in-
jury in the mdx mice.
Does dystrophin restoration by exon skipping improve
both force drop and muscle excitability?
In order to answer this question, we analyzed the effect
of the restoration of dystrophin protein expression on
force drop and muscle excitability following lengthening
contractions. For this purpose, we used AAV-U7snRNA-
mediated exon skipping of the Dmd ex23 previously
described in mdx mice [10]. Intramuscular injection of
mdx TA muscles with AAV1-U7ex23 resulted, 3 weeks
later, in a partial skipping of exon 23 of Dmd (Fig. 7a, b)
(p < 0.05), without affecting the total level of dystrophin
mRNA (Fig. 7c). A partial restoration of dystrophin protein
expression was confirmed by Western blot (Fig. 7d, e).
We found that 3 weeks after AAV1-U7ex23 injection,
the force drop following lengthening contractions was
reduced (Fig. 8a) (p < 0.05), and specific maximal force
was also increased by 19 % (Fig. 8b) (p < 0.05), confirming
our previous studies [12, 43]. Interestingly, the decrease in
CMAP (RMS) following lengthening contractions was also
reduced by AAV1-U7ex23 (Fig. 8a) (p < 0.05). Another
novel result from this experiment was that the changes in
force were closely related to those of CMAP during both
the lengthening contractions and recovery in both mdx
and mdx mice injected with AAV1-U7ex23 (Fig. 8c), with
a good correlation between CMAP and absolute maximal
force (r2 = 0.66) (p < 0.0001). Together, these results indi-
cate that the beneficial effect of restoration of dystrophin
expression on the force drop following lengthening con-
tractions in mdx mice was mediated by the prevention of
the CMAP impairment, i.e., reduced muscle excitability.
Discussion
The force drop in mdx mice is mainly due to reduced
muscle excitability
The present study reveals for the first time that lengthening
contractions induced a loss of TA muscle excitability in
mdx mice, independently from major neuromuscular trans-
mission failure. Firstly, we found that CMAP was reduced
following lengthening contractions in mdx mice, in agree-
ment with a previous study [18]. Secondly, we reported that
the voltage needed to elicit 50 % of maximal force increased
when the mdx muscle was directly stimulated without the
need of neuromuscular transmission, indicating that there
was an increased threshold for action potential generation
following lengthening contractions. Thirdly, we found that
the reduced CMAP following lengthening contractions did
not result from major neuromuscular transmission failure
in mdx, despite subtle morphological derangements of the
neuromuscular junctions.
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Importantly, we provided evidence that reduced muscle
excitability contributes to the immediate force drop follow-
ing lengthening contractions in mdx mice. Firstly, we found
a strong relationship between CMAP and force following
lengthening contractions and recovery in mdx mice.
Secondly, the force drop following lengthening contrac-
tion can be mimicked by an experimental reduction in
muscle excitation, using a neuromuscular transmission
Fig. 6 Myofribrillar function, muscle fiber ultrastructure, and optimal muscle length following lengthening contractions in the TA muscle from mdx
mice and effect of prior cardiotoxin injection. a Calcium maximally activated force of skinned muscle fibers (myofibrillar function) after nine
lengthening contractions. b, c Representative images of electron microscopy from mdx mouse illustrating the absence of morphological alterations
following nine lengthening contractions (c) as compared to before lengthening contractions (b). d Force drop following nine lengthening
contractions in mdx mice, muscles were stretched to try to obtain a new optimal length (L0). e Force drop following lengthening contractions in the
cardiotoxin-treated (freshly regenerated) mdx muscle. C57 mice were also shown. f Maximal force before lengthening contractions (initial) in mdx
muscle treated with cardiotoxin. C57 mice were also shown. 0LC before lengthening contractions, 9LC after nine lengthening contractions, 9LC + newL0
muscles were stretched to try to obtain a new optimal length (L0) after nine lengthening contractions, Cardio muscle injected with cardiotoxin
3 weeks before, a significantly different from before lengthening contractions (p < 0.05), b significant difference between strains (p < 0.05), c signifi-
cantly different from 9LC (p < 0.05), d significantly different from C57 (p < 0.05). n≥ 20 per group for a; n = 7–10 per group for d–f
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Fig. 7 (See legend on next page.)
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blocker (tubocurarine). Thirdly, improving muscle ex-
citability (via increased dystrophin expression) follow-
ing lengthening contractions and the recovery also
reduces the force drop. This mechanism of force drop
is also plausible for C57 mice since we found that a
marked force drop following lengthening contractions
in C57 mice was associated with a reduced CMAP
(Fig. 3e).
Another major and novel finding of the present study
was that the impaired muscle excitability not only contrib-
utes to the force drop following lengthening contractions
but it is the major contributor. In fact, there was no major
neuromuscular transmission failure, and neither excitation-
contraction coupling nor myofibrillar function was altered
following lengthening contractions. However, it is not im-
possible that a different muscle studied and/or protocol of
lengthening contractions can also alter myofibrillar function
[20] and/or neuromuscular transmission [16]. Mild injury
may primarily impact excitability and be rapidly reversible
(as in the present study) while more severe injury may re-
sult in additional, more slowly reversible effects (including
neuromuscular transmission failure, reduced myofibrillar
function) [16, 20].
Possible changes in K+, Na+, Cl−, and calcium transar-
colemmal gradients following lengthening contractions
could theorically explain the reduced muscle excitability
in mdx mice, i.e., generation/propagation of action po-
tentials in response to stimulation. As one possibility,
lengthening contractions could cause micro-tears in the
mdx muscle due to the lack of dystrophin, which leads
to membrane potential depolarization and inactivation
of Na+ channels. However, our results concerning the ef-
fects of different channels and pump modulators (mexi-
letine, salbutamol) suggest that Na+ channel and Na+,K+
pump are not involved in the membrane dysfunction
leading to reduced excitability following lengthening
contractions. At the basal state (before the lengthening
contractions), no clear alteration in the electrophysiology
of these sarcolemnal channels [44] supports the notion
that their aggravated impairment by lengthening contrac-
tions can play a role in the reduced muscle excitability. In
contrast, we found that 9AC, a Cl− channel inhibitor in-
creasing excitability, reduced the force drop, suggesting
that lengthening contractions could further increase chlor-
ide conductance in mdx mice. It was previously reported
that chloride conductance is already increased in mdx
mice at the basal state [45]. These results suggest that Cl−
channel dysfunction could contribute to the reduced excit-
ability following lengthening contractions in mdx mice.
However, the only way of determining if Cl− channels are
affected is by measuring their current before and after the
lengthening contractions. Clearly, future electrophysio-
logical studies are needed to explore the dysfunction of
membrane channels in mdx mice.
Since the force drop was marked and we found no
other major alterations than reduced muscle excitability,
it is very likely that a great number of unexcited TA
muscle fibers do not contribute to muscle force produc-
tion following lengthening contractions in mdx mice. In
line, a recent study [18] reported an increased number
of depolarized muscle fibers following lengthening
contractions in mdx mice, fibers that are very likely
not excitable. It remains to be determined whether the
mechanisms responsible for the reduced muscle excit-
ability are related to sarcolemmal damage following
lengthening contractions as shown by the presence
within a few fibers of impermeant dyes [5, 6] and the
presence of 12 % malformed fibers exhibiting alter-
ations in action potential kinetics at the basal state
[46] in mdx mice.
The force drop is related to dystrophin
The force drop following lengthening contractions was
not increased by prior myotoxic agent injection in mdx
mice, indicating that the greater susceptibility to contrac-
tion induced injury is not explained by the presence of
freshly regenerated dystrophic fibers that could be more
fragile, i.e., susceptible to contraction-induced injury. The
greater force drop is also not a hallmark of muscles af-
fected by neuromuscular disorders. Indeed, a greater force
drop following lengthening contractions is also observed
in alpha-sarcoglycan null mice [20] but not in collagen
6A1 null mice, whereas the force drop was reduced in des-
min null mice [47]. Together, these findings emphasized
the specific role of dystrophin and dystrophin-associated
complex in preventing the force drop following length-
ening contractions. This notion is also supported by
the preclinic therapies based on dystrophin restoration
since increased dystrophin expression reduced the force
drop following lengthening contractions in mdx mice
(see below).
(See figure on previous page.)
Fig. 7 Partial restoration of dystrophin expression in the TA muscle from mdx mice injected with AAV1-U7ex23. a RT-PCR analysis of Dmd exon
23 skipping in mdx mice injected with AAV1-U7ex23. b Quantification of Dmd exon 23 skipping in mdx mice injected with AAV1-U7ex23,
c Dystrophin total mRNA level in mdx mice injected with AAV1-U7ex23. d Western blot analysis of dystrophin protein expression in mdx
mice injected with AAV1-U7ex23, e Quantification of dystrophin protein expression in mdx mice injected with AAV1 U7ex23. U7-ex23 AAV1-U7ex23,
Mdx mdx muscle injected with saline, Mdx + U7ex23 mdx muscle injected with AAV1-U7ex23, c significant difference with non-injected muscle
(p < 0.05). n = 6–10 per group
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Dystrophin-based therapy improves muscle excitability
It is thought that the greater susceptibility to contraction-
induced damage initiates repeated degeneration/regener-
ation cycles leading to muscle weakness and wasting in
DMD. The greater immediate force drop following length-
ening contractions is also an important tool for testing
preclinic dystrophin-based therapies for DMD: exon skip-
ping therapy [9–11], microdystrophin therapy [8, 13], dual
dystrophin/myostatin therapy [12, 43], dual dystrophin/
follistatin therapy [14], and dual dystrophin/nNOS therapy
[15]. It has been well established that these dystrophin-
based therapies improves the immediate force drop fol-
lowing lengthening contractions in mdx mice [8–15].
In the present study, we demonstrated for the first
time that exon skipping-based dystrophin restoration
(via AAV1-U7ex23) mediates its beneficial effect by pre-
venting the large reduction in muscle excitability in mdx
mice, at least in the TA muscle. Thus, it is very likely
that the other preclinic interventions also improve muscle
action potential generation/conduction following lengthen-
ing contractions, in particular antisense oligonucleotide-
mediated splice modification, currently one of the most
promising therapeutic strategies for DMD [9, 11].
Moreover, it is possible that dystrophin restoration also
contributes to the reduced muscle weakness by improving
muscle excitability at the basal state (before lengthening
contractions) since specific maximal was 19 % increased
by AAV1-U7ex23.
Conclusions
Our findings revealed that (i) dystrophin is needed to
maintain muscle excitability following lengthening con-
traction and (ii) the reduced muscle excitability largely
contributes to the greater immediate force drop following
lengthening contractions in the TA muscle from mdx mice.
Importantly, we evidenced that dystrophin-based therapy in
mdx mice reduces this force drop following lengthening
contractions via improved muscle excitability. Thus, the
present study provides new insights that are relevant not
only for DMD etiology but also for treatment. To enhance
efficacy of dystrophin-based therapies, innovative means
are needed to help to maintain muscle excitability following
lengthening contractions. This notion is important since
Fig. 8 Effect of partial dystrophin restoration in the TA muscle from
mdx mice. a Force and CMAP (RMS) drops following lengthening
contractions in mdx mice injected with AAV1-U7ex23. b Specific
maximal force and muscle weight before lengthening contractions
in mdx mice injected with AAV1-U7ex23. c Force and CMAP relation-
ship during lengthening contractions and 20 min recovery in mdx
and mdx mice injected with AAV1-U7ex23. U7-ex23 AAV1-U7ex23,
Mdx mdx muscle injected with saline, Mdx + U7ex23 mdx muscle
injected with AAV1-U7ex23, a significantly different from before
lengthening contractions (p < 0.05), c significant difference with non-
injected muscle (p < 0.05). n = 8–13 per group
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muscle inexcitability following high-force contractions
causes temporary muscle weakness and may be irre-
versible by contributing to muscle wasting in the long
term (such as denervation or unloading).
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